Research suggests that patients with high BMI levels may experience reduced efficacy of benralizumab due to systemic inflammation caused by elevated levels of obesity-related cytokines like TNF-α, IL-6, and leptin [66]. The gene discussed is TNF; the disease is obesity disorder.